Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc, a global consumer-health company listed on the LSE and NYSE, filed this Form 6-K for March 2024. The filing is dated 18 March 2024 and reports the filing of a preliminary prospectus supplement with the SEC.
Haleon’s principal product categories are Oral Health, Pain Relief, Respiratory Health, Digestive Health, Vitamins, Minerals and Supplements, and Other. Key brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum.
Capital markets and financial information
On 18 March 2024, Haleon filed a preliminary prospectus supplement to its shelf registration statement on Form F-3, originally filed on 3 July 2023. The supplement was submitted to the National Storage Mechanism and is available through the SEC.
This Form 6-K does not provide revenue, profit, cash flow, margin, debt, liquidity, offering size, pricing, proceeds, or other financial metrics. The filing text does not provide a clear value for any of these items.
Material changes versus the prior comparable period
No operating or financial-period comparison is provided. The material event is the filing of the preliminary prospectus supplement.
Guidance, outlook, risks and unusual items
- The announcement does not provide earnings guidance, operating outlook, or management forecasts.
- The prospectus-related communication is not an offer to sell or solicitation to buy securities and does not constitute a sale before applicable registration or qualification requirements are satisfied.
- Distribution may be restricted in certain jurisdictions. In the United Kingdom, the communication is directed only to specified relevant persons; in the EEA, it is directed only to qualified investors.
- Any offer may be withdrawn or revoked before notice of acceptance following the effective date, without obligation or commitment by Haleon.
Important facts for investors to verify
- Review the preliminary prospectus supplement and any subsequent final prospectus for the securities offered, offering size, pricing, use of proceeds, underwriting terms and risk factors.
- Confirm whether and when the relevant registration statement and offering became effective.
- Check subsequent SEC filings for completion, withdrawal, or amendment of the proposed offering.
- Consult Haleon’s latest annual and interim reports for current financial performance, debt, liquidity, cash flow and outlook, none of which are included in this Form 6-K.